ArticleInfection and immunity2008
Interleukin-12 and host defense against murine Pneumocystis pneumonia.
Article in Infection and immunity, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 48 citations in OpenAlex.
- Detection and Remediation of Pneumocystis murina Infections by Environmental Health Monitoring.Journal of the American Association for Laboratory Animal Science : JAALAS · 2025Article
- Pneumocystis jirovecii pneumonia in patients with lung cancer receiving immune checkpoint inhibitors: a retrospective nationwide population-based cohort study from South Korea.Discover oncology · 2025Article
- T-cell subsets inClinical & translational immunology · 2025Review
- Dynamics of host immune responses and a potential function of Trem2Respiratory research · 2024Article
- Detection of Cytokines and Collectins in Bronchoalveolar Fluid Samples of Patients Infected withJournal of fungi (Basel, Switzerland) · 2021Article
- New Insights into Blood Circulating Lymphocytes in HumanJournal of fungi (Basel, Switzerland) · 2021Article
- Immune Response inJournal of fungi (Basel, Switzerland) · 2021Review
- Immunization with Pneumocystis carinii A12BMC immunology · 2021Article
- Survey of the Transcription Factor Responses of Mouse Lung Alveolar Macrophages toPathogens (Basel, Switzerland) · 2021Article
- A Review of Clinical and Preclinical Studies on Therapeutic Strategies Using Interleukin-12 in Cancer Therapy and the Protective Role of Interleukin-12 in Hematological Recovery in Chemoradiotherapy.Medical science monitor : international medical journal of experimental and clinical research · 2020Review
- Pulmonary Innate Immune Response Determines the Outcome of Inflammation During Pneumonia and Sepsis-Associated Acute Lung Injury.Frontiers in immunology · 2020Review
- Alcohol-associated intestinal dysbiosis impairs pulmonary host defense against Klebsiella pneumoniae.PLoS pathogens · 2017Article
- Article
- Oral Immunization of Mice with Live Pneumocystis murina Protects against Pneumocystis Pneumonia.Journal of immunology (Baltimore, Md. : 1950) · 2016Article
- Pediatric Acute Respiratory Distress Syndrome: Fibrosis versus Repair.Frontiers in pediatrics · 2016Review
- Treatment with Interleukin-7 Restores Host Defense against Pneumocystis in CD4+ T-Lymphocyte-Depleted Mice.Infection and immunity · 2016Article
- The predominance of alternatively activated macrophages following challenge with cell wall peptide-polysaccharide after prior infection with Sporothrix schenckii.Mycopathologia · 2013Article
- Potential implication of new torque teno mini viruses in parapneumonic empyema in children.The European respiratory journal · 2013Article
- STAT4-dependent and -independent Th2 responses correlate with protective immunity against lung infection with Pneumocystis murina.Journal of immunology (Baltimore, Md. : 1950) · 2013Article
- Acute respiratory distress syndrome: new definition, current and future therapeutic options.Journal of thoracic disease · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Little is known about the role of the cytokine interleukin-12 (IL-12) in Pneumocystis pneumonia or its potential use as immunotherapy. We asked whether release of IL-12 is part of the normal host response to this infection and whether local treatment with IL-12 or gene transfer of IL-12 could accelerate clearance of infection. IL-12 was assayed by enzyme-linked immunosorbent assay in normal mice and in mice deficient in IL-12 after inoculation of Pneumocystis carinii. P. carinii-infected mice were treated with local instillation of IL-12 and gene transfer of the IL-12 gene. Inoculation of P. carinii into normal mice evoked a brisk release of IL-12 into lung tissue, and IL-12 P35-deficient mice showed delayed clearance of infection measured by PCR for P. carinii rRNA. In control mice, intranasal recombinant IL-12 accelerated clearance of infection, and this was associated with increased recruitment of inflammatory cells into lavage fluid and increased release of tumor necrosis factor alpha, IL-12, and gamma interferon. Similar results were observed in infected mice depleted of CD4+ lymphocytes by using in vivo transfer of the IL-12 gene in a replication-deficient adenoviral vector. IL-12 is part of the normal host response to infection with P. carinii. IL-12 therapy can enhance host resistance to infection in both normal mice and mice depleted of CD4+ T lymphocytes. A treatment effect of IL-12 is mediated through enhanced inflammatory cell recruitment into lung tissue and increased tissue concentrations of proinflammatory cytokines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.